Introduction
Levetiracetam (LEV) is approved as monotherapy for focal epilepsy and add-on therapy for myoclonic and tonic-clonic seizures. 1 It is absorbed quickly and almost completely over a range of oral doses 2 and is not metabolised via the hepatic cytochrome p450 system. Two thirds are excreted unaltered in the urine, while the rest is excreted in the urine as an inactive metabolite L057, formed by enzymatic hydrolysis of the acetamide group. 2 It has minimal protein binding 3 and a half-life of 6-8 h.
Previous studies have reported no significant interactions between LEV and other anti-epileptic medications (AEMs). [4] [5] [6] It has also been shown that the rate of LEV metabolism is stimulated to some extent by major enzyme-inducing AEMs, such as carbamazepine (CBZ), phenytoin and phenobarbital and that LEV clearance is 25-37% higher in patients who are taking enzymeinducing AEMs. 7 Serum LEV levels are not widely advocated and currently performed mainly for the purposes of monitoring those with impaired renal function 8 and the elderly. 9 Serum and plasma LEV levels have been used for pharmacokinetic and tolerability studies.
a single outpatient clinic. Each patient was fully aware of the experimental nature of the LEV blood level determinations and understood the difficulty encountered to have these performed. All gave informed consent to have the levels measured, sent interstate and understood that, at the time of measurement, there was no established predetermined therapeutic level. The investigation was undertaken in a prospective manner, using LEV levels as an adjunct to routine patient care. LEV levels were compared to seizure activity over a period of up to 1.8 years (0.2-1.8 years; mean: 1.0 AE 0.5) between 2010 and 2012. All LEV levels were determined in a single laboratory by high performance liquid chromatography (HPLC) analysis using solid phase extraction of LEV from serum or plasma with inclusion of an internal standard for accuracy. The column was washed twice with various buffers to remove other AEMs. LEV was extracted and quantitated using HPLC with ultraviolet (UV) detection. 14, 15 Concomitant AEM levels were measured in a different laboratory also run by the same pathologist. CBZ and valproate (VPA) levels were measured using Fluorescence Polarisation. Trough levels were taken. For CBZ, imprecision ranged between 2.9% and 3.0% and for VPA between 2.1% and 2.3%. The period used to determine this, for both AEMs, was 28/05/2012 to 28/05/2013. For CBZ, 688 measurements were made with the lowest mean being 11.5 mmol/L and the highest mean being 62.0 mmol/L. For VPA, 2024 measurements were made with the lowest mean being 233 mmol/L and the highest mean being 804 mmol/L. 16 Free CBZ and VPA levels were determined by filtering serum through a molecular filter to remove all proteins. This was then analysed on the Roche Integra. Immunoassay control level 1 was used as a control for filtration and performed within the first batch of sample of the day. At least 0.4 mL, and up to 1.0 mL, of serum was transferred to the inside of the reservoir. The reservoir was capped and, along with the filtrate cup labelled with the patient identifier, centrifuged, for 15 min at 3000 rpm, and the filtrate analysed as soon as possible.
17 Lamotrigine (LTG) serum/plasma trough levels were measured using HPLC with UV detection. 18 All patients had concomitant biochemical, renal, hepatic and haematological parameters monitored to exclude confounding problems. Seizure activity comprised five categories: ongoing seizures (<one month seizure-free); one to three months seizure-freedom; >three and <six months seizure-freedom; six months to one year seizure-freedom; and >one year seizure-freedom. Concomitant AEMs included CBZ, VPA, LTG and lacosamide (LCM). Both total and free CBZ and VPA were measured (both VPA and CBZ being highly protein bound 19 ). LCM levels were unavailable. The importance of free levels, when monitoring therapeutic drug levels in the management of epilepsy, has been shown previously within clinical management, to determine which AEM was the most likely cause for AEM toxicity with polytherapy. 20 Adopted therapeutic ranges were: 20-40 mg/L for LEV; 25-50 mmol/L for CBZ total; 6-13 mmol/L for CBZ free; 300-750 mmol/L for VPA total; 30-75 mmol/L for VPA free and 40-60 mmol/L for LTG, acknowledging all but LEV were measured in New South Wales laboratories and LEV was sent interstate to Queensland (hence different units). PWE were initiated on AEMs, other than LEV, with LEV added if there was insufficient efficacy or adverse events. Where appropriate, AEMs were reduced to LEV monotherapy. Doses were clinically determined, aiming for maximal seizure control with minimal adverse events, complemented by AEM levels.
In order to assess the relationship between LEV levels and LEV doses, the concentration/dose ratio was calculated for LEV monotherapy and LEV polytherapy patients.
Statistically significant difference between groups was determined using the z-test for proportions, with a p-value <0.05 and a two-tailed hypothesis suitable for non-normative data (http:// www.socscistatistics.com/tests/ztest/Default2.aspx, accessed on 29/11/2013). For mean concentration/dose ratios the t-test (with a p-value <0.05 and a two-tailed hypothesis) was adopted for determining statistically significant differences between two independent means (http://www.socscistatistics.com/tests/studentttest/Default2.aspx, accessed on 29/11/2013).
Results
Patients were aged 19-69 years (42 AE 14) ( Table 1) . Thirty-one (60%) were female. Twenty-seven (52%) had focal onset seizures, 21/ 52 (40%) had primary generalised seizures and four (8%) had unclassified seizures. Most common AEM combinations were LEV with CBZ for focal epilepsy or VPA for generalised epilepsy (dual therapy) and LEV with LTG and VPA (triple therapy) in generalised epilepsy (Table 1) .
Dosages were: 250-6000 mg/day for LEV (mean: 2919 mg/ day AE 1134); 600-1400 mg/day for CBZ (mean: 822 mg/day AE 227); 700-6000 mg/day for VPA (mean: 1931 mg/day AE 1561); 100-1600 mg/day for LTG (mean: 546 mg/day AE 346) and 100-600 mg/ day for LCM (only two patients).
Twenty-three (44%) were on LEV monotherapy. Concomitant AEM levels for three patients were excluded because insufficient levels precluded reliable data. LCM levels were unavailable thereby preventing assessment of LEV interaction with LCM but LEV levels for both PWE were therapeutic.
Absolute range of LEV levels was 2-100 mg/L (28 AE 17) with mean levels ranging from 4 to 71.5 mg/L (28.7 AE 14). Thirty-two (62%) had mean LEV levels within the therapeutic range. Thirty-six (69%) were seizure-free (Table 2) (p < 0.05), 29 of them (81%) were seizure-free for !six months of whom 18 (62%) were seizure-free for >one year (Table 3) .
Fourteen (27%) had sub-therapeutic mean LEV levels and six (12%) had supra-therapeutic mean LEV levels. 3 of 14 (21%) with sub-therapeutic LEV levels had ongoing seizures (p = 0.0025). One of six PWE (17%) with supra-therapeutic LEV levels experienced symptoms of toxicity (p = 0.0209). This patient reported increased seizure rate with exacerbation interpreted as toxicity and the relevant LEV level was 86 mg/L. Twenty-three (44%) were on LEV monotherapy of whom 16 (70%) had therapeutic mean LEV, 13 of whom (81%) were seizurefree (p = 0.0004) (5/13 (38%) for >six months and 6/13 (46%) for >one year), demonstrating the value of the adopted therapeutic window. Six of these 23 patients (26%) had sub-therapeutic mean LEV levels of whom one (17%) had ongoing seizures (p = 0.0209). 1 of 23 (4%) had supra-therapeutic mean LEV levels without toxicity suggesting that higher dosages may still be possible.
Twenty-nine (56%) were taking concomitant AEMs with 16/29 (55%) having therapeutic mean LEV levels (comparable to those on monotherapy (p = 0.2891)). Seven of these 16 (44%) were (Fig. 1) .
Eleven of 29 PWE (38%) were taking CBZ, all of whom had therapeutic total and free mean CBZ levels. Seven (64%) were seizure-free (3/7 (43%) for >six months and 2/7 (29%) for >one year). Four (36%) had therapeutic mean LEV levels and 2/4 (50%) were seizure free (one (50%) for >one year). Two (18%) had supratherapeutic mean LEV levels and both were seizure free for >six months (without toxicity). Five (45%) had sub-therapeutic mean LEV levels with one (20%) seizure-free for >six months and one (20%) seizure-free for >one year. The remaining three PWE had ongoing seizures (Fig. 2) .
14 of 29 (48%) PWE were taking VPA, all with therapeutic total mean VPA levels. Eight (57%) were seizure-free (2/8 (25%) for >six months and 5/8 (63%) for >one year). Nine (64%) had supratherapeutic free mean VPA levels and 6/9 (67%) were seizure-free (1/6 (17%) for >six months and 4/6 (67%) for >one year). No symptoms of toxicity were reported for these patients. Five (36%) had therapeutic free mean VPA levels and 2/5 (40%) were seizurefree (one (50%) for >six months and one (50%) for >one year). Nine (64%) had therapeutic mean LEV levels and 3/9 (33%) were seizurefree (1/3 (33%) for >six months and 2/3 (67%) for >one year). Three (21%) had sub-therapeutic mean LEV levels, all of whom were seizure-free (2/3 (67%) for >one year). Two (14%) had Table 3 Seizure activity for polytherapy patients. supra-therapeutic mean LEV levels, one of whom (50%) was seizure-free for >six months and one (50%) for >one year. No symptoms of toxicity were reported for these patients (Fig. 3) .
Discrepancy between total and free CBZ and VPA levels was reviewed. None of the CBZ treated PWE showed discrepancy but 8 of 14 PWE (57%) on VPA had a discrepancy between total and free levels.
13 of 29 (45%) PWE were taking LTG. Seven (54%) had therapeutic mean LTG levels and 2/7 (29%) were seizure-free (one (50%) for >one year). Three (23%) had sub-therapeutic mean LTG levels, two (67%) of whom were seizure-free (1/3 (33%) for >six months). Three (23%) had supra-therapeutic mean LTG levels with 1/3 (33%) being seizure-free (>one year). One of these three (33%) experienced symptoms of toxicity. This patient reported strange feelings, not thought to be seizures, interpreted as drug toxicity, with LTG level of 85.9 mmol/L. 8 of 13 (62%) PWE had therapeutic mean LEV levels and 1/8 (13%) was seizure-free (>one year) which was statistically significant (p = 0.0027). Two (15%) had supra-therapeutic mean LEV levels (one patient reporting increased seizure rate interpreted as toxicity) and one of these (50%) was seizure-free (>six months). Three (23%) had subtherapeutic mean LEV levels and all three were seizure-free (1/3 (33%) for >one year) (Fig. 4) .
Eleven of 52 PWE (21%) were on three AEMs (Table 1) . Seven (64%) had therapeutic mean LEV levels and one of whom (14%) was seizure-free (>one year) which was statistically significant (p = 0.0076). Three (27%) had sub-therapeutic mean LEV levels and all three were seizure-free (1/3 (33%) for >one year). One (9%) PWE had supra-therapeutic mean LEV levels, was seizure-free (>six months) and had no toxicity.
Nine of 11 PWE (82%) were taking LTG, five of whom (56%) had therapeutic mean LTG levels with 2/5 (40%) seizure-free (one for >one year). Two (22%) had sub-therapeutic mean LTG levels and both were seizure-free (one (50%) for >six months) while two (22%) had supra-therapeutic mean LTG levels, both with ongoing seizures and no toxicity.
Eight of 11 PWE (72%) were taking VPA, all having therapeutic total mean VPA levels and 3/8 (38%) were seizure-free (2/3 (67%) for >1 year). Four (50%) had therapeutic free mean VPA levels with 3/4 (75%) having ongoing seizures. Four (50%) PWE had supratherapeutic mean free VPA levels and 2/4 (50%) were seizure-free (one (50%) for >one year), all without toxicity.
Four of 11 PWE (36%) were taking CBZ all with therapeutic total and free mean CBZ levels. Two (50%) were seizure-free (one (50%) for >six months).
Mean concentration/dose ratios were compared for LEV monotherapy and polytherapy. The mean concentration/dose ratio for polytherapy was significantly lower than was the mean ratio for monotherapy (p = 0.0090). The mean LEV dose for monotherapy patients was 2401.8 mg/day (mean LEV level was 28.6 mg/L) and for polytherapy was 3077.0 mg/day (mean LEV level was 28.9 mg/L). The mean LEV dose for monotherapy patients was significantly lower than the mean dose for polytherapy (p = 0.0226), suggesting a need for higher LEV dosages in PWE who are on polytherapy.
Discussion
LEV reduced seizure frequency by 50% in a cohort of 1541 PWE with seizure-freedom in $60%. 21 In a study of 228 PWE, approximately 50% were seizure-free for >one year on a median dose of LEV of 1000 mg/day. 22 The current study reports 69%
seizure-free, of whom 81% were seizure-free for !six months and 62% >one year, suggesting improved efficacy when clinical decisions are complemented by blood level determination. Recommended LEV dosages range from 1000 to 4000 mg/day 23 with median dosage in the pivotal trials being 3000 mg/day. 9, 24 In this study, LEV doses range from 250 to 6000 mg/day (mean: 2778 mg/day) suggesting the application of blood levels, complementing clinical decision-making, allowed increased dosages in some patients but a mean dosage comparable to that within the literature. LEV is considered to be an effective add-on treatment across various seizure types in patients with refractory epilepsy. 25 The PWE in this study were prescribed LEV as adjunctive treatment and converted to monotherapy when possible. LEV monotherapy, monitored with blood levels, was more effective than was LEV with polypharmacy and demonstrated reduced concentration/dose ratio. 23 of the 52 PWE (44%) were on LEV monotherapy, 16 of whom (70%) had mean LEV levels within the therapeutic range and 13 of these 16 (81%) were seizure-free with 11/13 (85%) seizurefree for >six months and 6/13 (46%) >one year. The number of PWE who were seizure-free was statistically significantly higher than those with ongoing seizures (p = 0.0004).
Ben-Menachem and Falter 26 showed LEV monotherapy produced approximately 74% median reduction in partial seizure frequency. Korby et al. 27 showed 76% of LEV monotherapy patients were seizure-free, compared to 36% with polytherapy. With therapeutic LEV levels, 81% monotherapy and 44% polytherapy PWE were seizure-free (85% and 71% >six months, respectively) indicating enhanced efficacy when combining clinical decisionmaking with blood levels. This study demonstrated reduced LEV efficacy with polytherapy, requiring higher concentration/dose ratios and suggested LEV was affected by concomitant AEMs. The present study included 11/ 52 (21%) PWE requiring three AEMs (11/29 (38%) of those on polypharmacy) reflective of a more refractory spectrum of epilepsy in this cohort. The use of LEV levels, in conjunction with levels of concomitant AEMs, allows more specific adaptation of dosage regimen to patient needs. In the present study, dosages up to 6000 mg LEV were used without toxicity.
29 of 52 PWE (56%) were taking concomitant AEMs, of whom 16 (55%) had LEV levels within range and 7/16 (44%) were seizurefree, with 5/7 (71%) seizure-free for >six months and 4/7 (57%) >one year. These data were comparable with the monotherapy cohort.
This study suggested drug interactions between LEV and concomitant AEMs thereby confounding therapeutic levels with polypharmacy. Sixteen out of 29 (55%) PWE on polypharmacy had mean LEV levels within range compared with 70% of PWE on LEV monotherapy. Fourteen of 29 patients (48%) were taking VPA, of whom nine (64%) had mean LEV levels within range. Thirteen of 29 PWE (45%) were taking LTG, of whom eight (62%) had mean LEV levels within range. While all 11 PWE on CBZ had therapeutic total and free CBZ levels, 5/11 (46%) had subtherapeutic LEV of whom 2/5 (40%) were still seizing. This suggests CBZ may affect LEV metabolism although the mechanism is unclear.
The effect of LEV on concomitant AEMs also requires consideration. All PWE on CBZ (11/52) maintained therapeutic total and free CBZ levels, suggesting LEV has little effect on CBZ metabolism, noting that CBZ metabolism depends on the hepatic cytochrome p450 system which is not involved in LEV metabolism. 2, 28 Total VPA levels were therapeutic for all those on VPA (14/52) but 5/14 (36%) had therapeutic VPA free levels and 9/14 (64%) had supratherapeutic free levels, which suggests that LEV may impede VPA protein binding. The reason for this is unclear as LEV has minimal protein binding. 3 Many clinicians ignore VPA levels or rely more on free VPA levels 29 which, this study suggests, may be affected by concomitant LEV administration. The relationship between LEV and LTG co-administration is less predictable with half (7/13) maintaining therapeutic LTG levels and equal numbers (3/13) having either supra-or sub-therapeutic LTG levels. LEV and LCM interaction could not be adequately assessed but both patients had therapeutic LEV levels.
This study also suggests interactions between LEV and concomitant AEMs, via the concentration/dose ratio, with a lower ratio for polytherapy patients (p = 0.0090). The mean LEV dose for monotherapy was 2401.8 mg/day compared with 3077.0 mg/day for polytherapy patients (p = 0.0226). The mean LEV levels for both monotherapy and polytherapy were $29 mg/L, indicating that patients on polytherapy required higher dose of LEV to achieve similar blood levels.
This study demonstrated that the adopted LEV therapeutic range (20-40 mg/L) assisted in decision-making and better management of epilepsy, especially with monotherapeutic LEV. 40 mg/L may not be the maximal therapeutic level but allowed most PWE to experience reduced seizures with minimal adverse events.
This study reported significant possible drug interactions between LEV and concomitant AEMs, something, hitherto, considered insignificant but which may further explain impaired efficacy of LEV with polypharmacy. It showed that the interactions between LEV and concomitant AEMs may be unpredictable (as with LTG) providing additional support for use of blood level determination of both LEV and concomitant AEMs when treating PWE.
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